NASDAQ:RIGL
Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc.'s revenue grew 64.1% in fiscal 2025 to $294.3M while operating margin rose to 42.6%, its highest in 10 years. The diluted share count rose 6.5%.Summary generated from Rigel Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Mar 3, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$294.3M
Revenue growth+64.1%
Revenue, 5-yr CAGR+22.1%
Gross margin93.3%
Operating margin42.6%
Net margin124.7%
ROIC61.2%
Return on equity185.9%
Debt / equity0.13
Free cash flown/a
FCF marginn/a
Share count change+6.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 149 | 120 | 117 | 179 | 294 |
| Operating income | −12 | −56 | −20 | 24 | 125 |
| Net income | −18 | −59 | −25 | 17 | 367 |
| Free cash flow | 5 | −74 | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Sep 3, 2026 - 4Insider transaction report
Sep 3, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KDirector or officer change
Jul 1, 2026 - 8-KCompletion of an acquisition or disposition
Jun 17, 2026 - 8-KDirector or officer change
May 20, 2026 - 8-KEntry into a material agreement
May 12, 2026